US FDA Warns of Muscle Harm When Ingredients in Heart Drugs Merck & Co., Inc., Abbott Laboratories Combine

August 8, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WASHINGTON, Aug 8 (Reuters) - U.S. health officials warned the public on Friday about the risk of a rare type of muscle injury seen when the cholesterol drug simvastatin is combined with the anti-arrhythmia medicine amiodarone.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Postmarket research

Merck & Co. Food and Drug Administration (FDA) Abbott Laboratories